			Sheet · 1 of 5
APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	ATTY DOCKET NO.	SERIAL NO.
ATT I	•	PKZ-035CPA2CN2	10/629,340
QIST OF PERLICATIONS	S CITED BY APPLICANT	APPLICANT	
(Us ek everal she	ets if necessary)	Margret Oethinger e	t al
DEC 0 1 2004 8		FILING DATE	GROUP
	·	July 28, 2003	1654
73. 8			

U.S.	PATENT	DOCUM	JENTS
v.v.	INILINI		MEIAIO

EXAMINER INTIAL	ADE	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
CC	A1	4,806,529	2/89	Levy	514	154	WATE TO THE
CC	A2	5,021,407	6/91	Levy	514	154	
CC.	A3	5,064,821	11/91	Levy	514	154	
CC.	м	5,179,096	01/93	Gentilini et al.	514	253	
tr tr	AS	5,258,372	11/93	Levy	514	154	
Ca	Aß	5,589,470	12/96	Levy	514	154	<u>,,,</u>
CC	A7	5,789,188	8/98	Rothstein, et. al.	435	29	······································
22	A8	5,811,412	9/98	Levy	514	154	
	A9	5,817,793	10/98	Levy	536	24.1	
if	A10	5,989,832	11/99	Trias et al.	435	7.2	
Ch	A11	6,068,972	5/00	Levy	435	4	•
V 4 3 4			FOF	REIGN PATENT DOCUMENTS			
		DOCUMENT NUMBER	DATE	Constant		<u> </u>	

i	'	DOCUMENT NUMBER	DATE	Соципну	CLASS	SUBCLASS	TRANSLATION		1
	A12	14/0 00/00/00			•		YES	NO	l
CC	^"	WO 96/33285	10/96	PCT			X		1
CC	A13	WO 99/37667	01/99	PCT			X		ĺ
ff	A14	WO 99/17607	04/99	PCT			X		١
CC	A15	WO 99/17760	04/99	PCT			X		Ì
CC	A16	WO 99/17791	04/99	PCT			X		l
CC	A17	WO 99/32657	07/99	PCT			X		l
CE	A18	WO 99/37800	07/99	PCT			X	· · · · · · · · · · · · · · · · · · ·	
CF	A19	WO 00/01714	01/00	PCT			X		
CC	A20	WO 00/32196	06/00	PCT			X		
CC	A21	WO 96/23075	08/00	PCT			×		

	OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)											
FF	A22		Aono, Rikizo (1998) "Improvement of O	no, Rikizo (1998) "Improvement of Organic Solvent Tolerance Level of Escherichia Coli by rerexpression of Stress-Responsive Genes", Extremophiles Vol. 2 p. 239-248;								
Examine	_	_	free 2	Date Considered 4/05								
*EXAMIN	IER:		Initial if-reference considered, whether or if not in conformance and not considered.	not citation is in conformance with MPEP 609; Draw line through citation include copy of this form with next communication to applicant.								

	Sheet 2 of 5
ATTY DOCKET NO.	SERIAL NO.
PKZ-035CPA2CN2	10/629,340
APPLICANT	
Margret Oethinger et	al,
FILING DATE	GROUP

APPLICANT FACSIMILE OF FORM PTO-1449 REV 7-80 BUBLICATIONS CITED BY APPLICANT several sheets if necessary) DEC 0 1 2004 July 28, 2003 1654

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) BANG Brenwald, N.P. et al.Fluoroquinolone Resistance in Streptococcus pneumoniae by an Efflux Mechanism, Abstr of the 37th Inersc. Conference on Antimicrobial Agents and Chemotheraphy; Buysse, J.M. et al. (1996) "Mutation of the AcrAB antibiotic efflux pump in Escherichal coli confers susceptibility to oxazolidinone antibiotics" Abstracts of the Interscience Conference Of CC Antimicrobial Agents And Chemotherapy, Vol. 36, No. 0, pp. 41. 36th ICAAC (International Conference of Antimicrobial Agents and Chemotherapy) New Orleans, Louisiana, USA. September 15-18; Cohen, Seth P. et al. (1989) "Cross-Resistance to Fluoroquinolones In Multiple-Antibiotic-Resistant (Mar) Escherichia Coli Selected By Tetracycline Or Chloramphenicol: Decreased Drug FE. Accumulatin Associated With Membrane Changes In Addition To OmpF Reduction" Antimicrobial Agents and Chemotherapy, Vol. 33, No. 8, pp. 1318-1325; Fourner, B. et al. A mutation in the griB Gene of topoisomerase IV from Staphlococcus aureus Causes an Increase of Fluoroquinolone Resistance and A Decrease of coumarin Resistance, CC Abstracts of the 37th Inerscience Conference on Antimicrobial Agents and Chemotheraphy; Goldman, John D. (1996) "Multiple Antibiotic Resistance (mar) Locus Protects Escherichia Coli. CC From Rapid Cell Killing by Fluoroquinolones" Antimicrobial Agents and Chemotherapy, Vol. 40, No. 5, pp. 1266-1269: Gustafson, John E. et al. (1999) "Growth In The Presence of Salicylate Increases Fluoroquinolone Resistance In Staphylococcus Aureus" Antimicrobial Agents and Chemotherapy, vol. 45, No. 4 pp. 990-992; † Shenk Hooper DC, et.al...(1987) "Mechanisms of action of and resistance to ciprofloxacin". Am J. Med 82(4A); Hullen, V. et al. (1998) "Induction of the mar Phenotype Is a Possible Cause for The Development of Fluoroquinolone Resistance In Escherichia Coli," Antimicrob. Resist. Action; Kern, W.V. et al. Selection of high-level fluoroquinolone-resistant Echerichia coli mutants invitro:involvement of the mar or Sox system, Abstracts of the 37th Inerscience Conference on Antimicrobial Agents and Chemotheraphy; Levy, Colin W et al. (1999) "Molecular Basis of Triclosan Activity" Nature, Vol. 398, pp. 383-384; Lewis, Kim et al. (1996) "Multidrug Resistance Pumps Provide Broad Defense" ASM News, Vol. 63, No. 11 pp. 605-610; Lewis, Kim (1994) "Multidrug Resistance Pumps In Bacteria; Variations On a Theme"TIBS 19, pp. 119-123: Lomovskaya, O. et al. "Indentification and characterization of Efflux Pump Inhibitors in P. aeruginosa", Abstact no. F-1264, Poster Presentation at the 38th Inerscience Conference on Antimicrobial Agents and Chemotheraphy; Lomovskaya, O. et al. "Inhibitors of Efflux Pumps in Pseudomonas aeuruginosa Potentiate the CE Activity of the Flurorquinolone Antibacterial Levoflaxacin", Abstact no. F-1265, Poster Presentation at the 38th Inerscience Conference on Antimicrobial Agents and Chemotheraphy; Lomovskaya, O. et al. "Effux Pump Inhibitors (EPIs) Enhance the Activity of antrimicrobial Agents against a road Selection of Bacteria", Abstact no. F-1266, Poster Presentation at the 38th Inerscience Conference on Antimicrobial Agents and Chemotheraphy Date Considered 4 **Examiner**B

*EXAMINER:

Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	APPLICANT	FACSIVE	E OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE		Sheet 3 of 5			
	OT P	E	E OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	PKZ-035CPA2CN2	10/629,340			
	LIS Dec 0	(PUBLICATIONS CITED BY APPLICANT several sheets if necessary)	Margret Oethinger et al.				
B	000	1 2001		July 28, 2003	1654			
**	CA TRAD	MARY	OTHERS (including Author, Title,	Date Pertinent Pages Etc.)				
	FF-	C1	Lomovskaya, O. et al. "Prevalence of Ef PseudomonEffux Pump Inhibitors (EPIs road Selection of Bacteria", Abstact no. Conference on Antimicrobial Agents and	fflux Pump Overexpression Ar b) Enhance the Activity of antri F-1267, Poster Presentation and d Chemotheraphy	microbial Agents against a at the 38 th Inerscience			
	SS	CS	Lomovskaya, O. et al. "Potentiation of Landibitor ('EPI) in Mouse Models of Infection Poster Presentation at the 38 th Inerscient Chemotheraphy;	evofloxacin (levo) by a Broad-	inasa" Abstact no F-1268			
	CC	8	Lomovskaya, O. et al. "Inhibitors of Fund Presentation at the 38 th Inerscience Cor	gal Efflux Pump", Abstact no.	F-1269, Poster			
	SS	C4	Inhibition of Efflux Pumps in Pseudomor Chemotherapy, Vol. 43, No. 6, pp. 1340	a Genetic Approach To Evalu nas Aeruginosa" Antimicrobial I-1346;	ate the Consequences of Agents and			
	CC	CS	Markham PN, et al. (1999) "Multiple nove Staphylococcus aureus. Antimicrob Age	el inhibitors of the NorA multid ents Chemother, :43(10):2404-	rug transporter of			
	ff	C6	Ma, Dzwokai et al. (1995) "Genes acrA a Escherichia Coli" Molecular Microbiology	and acrB Encode A Stress-Ind	luced Efflux System of			
	ff	C7	Ma, Dzwoka et al. (1996) "The Local Report of acrAB Genes of Escherichia Coli by GNo. 1, pp. 101-112;	pressor AcrR Plays A Modula Global Stress Signals" Molecul	ting Role In The Regulation ar Microbiology, Vol. 19,			
	SF	CB.	McMurry, Laura et al. (1998) "Overexpre triclosan in Escherichia coli: FEMS Micro	ession of marA, soxS, or acrAl obiol. Lett. 166(2), 305-309:	3 produces resistance to			
	FF	Ca.	McMurry, Laura et al. (1994) "Active Efflic Strains and in Multiple-Antibiotic-Resista Chemotherapy, Vol. 38, No. 3, pp. 542-5	ux of Chloramphenicol In Susant (Mar) Mutants" Antimicrobi	ceptible Escherichia Coli al Agents and			
	ff	C10	Miller, Paul F and Sulavik, Mark C. (1996 Multiple-Antibiotic Resistance In Escheric 441-448;	6) "Overlaps and Paralels In T chia Coli" Molecular Microbiol	ogy, Vol. 21, No. 3, pp.			
	je	C11	Moken, Merri C. et al. (1997) "Selectin of Escherichia Coli by Using the Disinfectar Antimicrobial Agents and Chemotherapy	nt Pine Oil: Roles of the mar a $\sqrt{\text{Vol. 41}}$, No. 12, pp. 2770-277	ind acrAB Loci" 72;			
	<u>f</u> f	C12	Nikaido, Hiroshi (1996) "Multidrug Efflux Bacteriology Vol. 178, No. 20 pp. 5853-5	Pumps of Gram-Neative Bact 5859;	eria" Journal of			
	G F	C13	Nikaido, Hiroshi et al. (1998) "Multidrug E Only Those β-Lactam Antibiotics Contain 180, No. 17, pp. 4686-4692;	Efflux Pump AcrAB of Salmon ning Lipophilic Side Chains" Jo	ournal of Bacteriology, Vol.			
	4	-	Oethinger, M. et al., (1998) "Ineffectiventhe Absence of the AcrAB Multidrug Effluon Antimicrobial Agents and Chemothera no. C125);	ux Pump" Preseented at the 3	B th Interscience Conference			
	Examiner	- /\						

*EYAMINED

Initial Leterence considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

			Sn88(4 0) 5	
APPLICANT FACSIMILE OF REV 7-80	FORM PTO-1449 U.S. DEPARTMENT (PATENT AND TRADE		BERIAL NO.	
MIPE	•	PKZ-035CPA2CN2	2 10/629,340	
	BLICATIONS CITED BY API			
/ (Uś	several sheets if necessary) Margret Oethinge	r et al.	
DEC 0 1 2004	N	FILING DATE	GROUP	
8	<i>i</i>	July 28, 2003	1654	
17 2	~			

OTHERS (including Author, Title, Date, Pertinent Pages, Etc.) Oethinger, Margret et al. (1998) "Overexpression of the marA or soxS Regulatory Gene in Clinical Topoisomerase Mutants of Escherichia Coli" Antimicrobial Agents and Chemotherapy, Vol. 42. W No. 8 pp. 2089-2094; Oethinger, Margret et al. (1998) "Associate of Organic Solvent Tolerance and Fluoroquinolone 66 Resistance In Clinical Isolates of Escherichia Coli* Journal of Antimicrobial Chemotherapy, Vol. 41, pp. 111-114; Okusu, Haruko et al. (1996) "AcrAB Efflux Pump Plays a Major Role in the Antibiotic Resistance Phenotype of Escherichia Coli Multiple-Antibiotic-Resistance (Mar) Mutants" Journal of Bacteriology Vol. 178, No. 1 pp. 306-308; 04 Park, Yoon-Hee et al. (1996) "Molecular Analysis of Fluoroguinolone-Resistance in Escherichia Coli on the Aspect of Gyrase and Multiple Antibiotic Resistance (mar) Genes" Medical Journal, Vol. 39, No. 4 pp. 514-540; **O**5 Paulsen, Ian T. et al. (1996) "Proton-Dependent Multidrug Efflux Systems" Microbiological Reviews Vol. 60, No. 4 pp. 575-608; Sanchez, Laura et al. (1997) "The acrAB Homolog of Haemophilus influenzae Codes for a Functional Multidrug Efflux Pump, Vol 179(21), pp. 6855-6857; Schmitz, Franz-Josef et al. (1998) "The Effect of Reservine, An Inhibitor of Multidrug Efflux Pumps, On The In-Vitro Activites of Ciprofloxacin, Sparfloxacin and Moxifloxacin Against Clinical Isolates of Staphylococcus Aureus" Journal of Antimicrobial Chemotherapy Vol. 42, pp. 807-810; Spratt, Brian G. (1994) "Resistance to Antibiotics Mediated by Target Alterations" Science Vol Sun, Li et al. (1996) "NorA Plasmid Resistance to Fluoroquinolones: Roles of Copy Number and norA Frameshift Mutations" Antimiscrobial Agents and Chemotherapy Vol. 40, No. 7, pp 1665-1669: D10 Tanaka, Toshihiko et al. (1997) "RobA-induced multiple antibiotic resistance largely depends on FF the activation of the AcrAB efflux" Microbiol. Immunol. 41(9), 697-702; D11 Tankovic J, et al. (1996) "Contribution of mutations in gyrA and parC genes to fluoroquinolone resistance of mutants of Streptococcus pneumoniae obtained in vivo and in vitro" Antimicrob W Agents Chemother;40(11):2505-10; White, David G. et al. (1997) "Role of the acrAB Locus In Organic Solvent Tolerance Mediated By CC Expression of marA, soxS, or robA in Escherichia Coli" Journal of Bacteriology Vol. 179, No. 19 pp. 6122-6126. Date Considered A Examiner *EXAMINER: Initial if-reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

	APPLICANT	FACSILE	F OF FORM PTO 1110	110 05010					eet 5 of 5			
•	APPLICANT FACSIMILE OF FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF PUBLICATIONS CITED BY APPLICANT (Use saveral sheets if necessary)					PKZ-035CPA20	าเกา	10/629,340				
						APPLICANT 10/029,340			<u> </u>			
	1/				ssary)	Margret Oethin	ger <i>et al</i>					
	060	0 1	2004 8			July 28, 2003		1654				
	3							1034				
	45	ine		 	U.S. PATENT DO	CUMENTS		· · · · · · · · · · · · · · · · · · ·				
	EXAMINER UNITIAL	Ε1	OOCUMENT NUMBER	DATE		YAME	CLASS	SUBCLASS	FILIN IF APP	IG DATIE ROPRIATE		
	ff		6,326,391	12/01	Markham <i>et al.</i>		514	410				
	56	E2	6,346,391	02/02	Oethinger et al.		435	32				
				FOI	REIGN PATENT D	OCUMENTS	<u> </u>		<u> </u>			
			DOCUMENT NUMBER	DATE		COUNTRY	CLASS	SUBCLASS	TRAN	SLATION		
,			 	- CATE					YES	NO		
												
						 						
		OTHERS (including Author, Title, Date, Pertinent Pages, Etc.)										
			- Omen	· /moladii	ing Addition, Trate, D	zate, Fertinent Fage	s, E.C.)					
				The second secon	المُورِينَّةِ اللَّهِ الْمُؤَرِّدُ مِنْ الْمُؤَرِّدِينَ الْمُؤَرِّدِينَ الْمُؤَرِّدِينَ الْمُؤَرِّدِينَ الْمُؤ والمُورِينِينِ اللهِ الله	A Company Company	langin. Bendara		•			
•			·			2.3.2.						
	· · · · ·	\dashv				·						
		·										
												
		 ∤				-						
												
												
								 -	 			
ı	Examiner			\sim		Date Considered	03					
	'EXAMIN	ER:	Initial if I	reference co	ensidered, whether or r	ot citation is in conforma	ance with Mi	PEP 609; Draw	line throu	gh citation		
ł			if not in a	contomance	a and not considered.	Include copy of this form	n with next c	ommunication	o applicar	nt.		